Dianthus Therapeutics, Inc.

NasdaqCM:DNTH Stock Report

Market Cap: US$1.7b

Dianthus Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Marino Garcia

Chief executive officer

US$8.8m

Total compensation

CEO salary percentage6.78%
CEO tenure4.2yrs
CEO ownershipn/a
Management average tenure2.5yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

We Think Dianthus Therapeutics (NASDAQ:DNTH) Can Afford To Drive Business Growth

Jul 10
We Think Dianthus Therapeutics (NASDAQ:DNTH) Can Afford To Drive Business Growth

We're Not Very Worried About Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn Rate

Mar 15
We're Not Very Worried About Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn Rate

Dianthus Therapeutics (NASDAQ:DNTH) Is In A Good Position To Deliver On Growth Plans

Jul 03
Dianthus Therapeutics (NASDAQ:DNTH) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Marino Garcia's remuneration changed compared to Dianthus Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$126m

Jun 30 2025n/an/a

-US$115m

Mar 31 2025n/an/a

-US$101m

Dec 31 2024US$9mUS$600k

-US$85m

Sep 30 2024n/an/a

-US$67m

Jun 30 2024n/an/a

-US$57m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$496kUS$175k

-US$44m

Compensation vs Market: Marino's total compensation ($USD8.84M) is above average for companies of similar size in the US market ($USD5.37M).

Compensation vs Earnings: Marino's compensation has increased whilst the company is unprofitable.

CEO

Marino Garcia (59 yo)

4.2yrs
Tenure
US$8,843,300
Compensation

Mr. Marino Garcia, M.B.A., serves as President and Chief Executive Officer at Dianthus Therapeutics, Inc, since November 2021 and its Director since September 2023 also served as its Secretary until 2024....

Leadership Team

NamePositionTenureCompensationOwnership
Marino Garcia
President4.2yrsUS$8.84mno data
Ryan Savitz
Chief Financial Officer & Chief Business Officer2.3yrsUS$4.00m0%
$ 0
Simrat Randhawa
Executive VP and Head of R&D3.7yrsUS$4.04m0.0093%
$ 158.7k
Edward Carr
Chief Accounting Officer2.3yrsno datano data
Judson Taylor
Senior VP & Head of Technical Operationsno datano datano data
Jennifer Ruff
VP and Head of Investor Relations & Corporate Affairs2.2yrsno datano data
Adam Veness
Senior VP2.6yrsno datano data
Kristina Maximenko
Chief People Officerno datano datano data
Rashieda Gluck
Head of Clinical Development Operationsno datano datano data
Scott Nogi
Head of Business Operationsno datano datano data
Debra Segal
Head of Regulatory Affairsno datano datano data
Polly Hanff
Head of Qualityno datano datano data
2.5yrs
Average Tenure
55yo
Average Age

Experienced Management: DNTH's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marino Garcia
President2.3yrsUS$8.84mno data
Alison Lawton
Independent Chairman of the Board5.1yrsUS$252.91k0%
$ 0
Sujay Kango
Independent Directorless than a yearno datano data
Anne McGeorge
Independent Director6.6yrsUS$238.41k0%
$ 0
Jonathan Violin
Independent Director6.5yrsUS$227.41k0%
$ 0
Steven Romano
Independent Director1.3yrsno datano data
Paula Soteropoulos
Independent Director2.3yrsUS$239.91k0%
$ 0
Simon Read
Directorless than a yearno datano data
2.3yrs
Average Tenure
61yo
Average Age

Experienced Board: DNTH's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/05 00:29
End of Day Share Price 2026/01/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dianthus Therapeutics, Inc. is covered by 16 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Joel BeattyBaird
null nullBaird